HUP9900822A2 - Piperazinszármazékok, eljárás előállításukra, ezeket tartalmazó gyógyszerkészítmények és eljárás tachikinin-mediált betegségek kezelésére - Google Patents
Piperazinszármazékok, eljárás előállításukra, ezeket tartalmazó gyógyszerkészítmények és eljárás tachikinin-mediált betegségek kezeléséreInfo
- Publication number
- HUP9900822A2 HUP9900822A2 HU9900822A HUP9900822A HUP9900822A2 HU P9900822 A2 HUP9900822 A2 HU P9900822A2 HU 9900822 A HU9900822 A HU 9900822A HU P9900822 A HUP9900822 A HU P9900822A HU P9900822 A2 HUP9900822 A2 HU P9900822A2
- Authority
- HU
- Hungary
- Prior art keywords
- mediated diseases
- producing
- pharmaceutical compositions
- compositions containing
- piperazine derivatives
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 3
- 102000003141 Tachykinin Human genes 0.000 title abstract 2
- 201000010099 disease Diseases 0.000 title abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 2
- 230000001404 mediated effect Effects 0.000 title abstract 2
- 108060008037 tachykinin Proteins 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 150000004885 piperazines Chemical class 0.000 title 1
- 229940066771 systemic antihistamines piperazine derivative Drugs 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- -1 (2R)-1-[3,5-bis(trifluoromethyl)benzoyl]-2-(1H-indol-3-ylmethyl)-4-[N-(4- methyl-1-piperazinyl)-carbamoyl-methyl]-piperazine Chemical compound 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 150000004701 malic acid derivatives Chemical class 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Abstract
A találmány tárgya (I) képletű (2R)-1-[3,5-bisz(triflűőr-metil)-benzőil]-2-(1H-indől-3-il-metil)-4-[N-(4-metil-1-piperazinil)-karbamőil- metil]-piperazin vagy ennek fűmársavas sója. A találmánytárgya tővábá előállítási eljárás a fenti vegyület előállítására,valamint gyógyszerkészítmény, amely a fenti vegyületet tartalmazza,illetve alkalmazási eljárás amelyben ezt gyógyszerként felhasználjáktachikinin-mediált betegségek kezelésére vagy megelőzésére. ŕ
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US45017695A | 1995-05-25 | 1995-05-25 |
Publications (2)
Publication Number | Publication Date |
---|---|
HUP9900822A2 true HUP9900822A2 (hu) | 1999-06-28 |
HUP9900822A3 HUP9900822A3 (en) | 1999-11-29 |
Family
ID=23787083
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HU9900822A HUP9900822A3 (en) | 1995-05-25 | 1996-05-21 | Piperazine derivatives, process for producing them, pharmaceutical compositions containing them and method for treating tachykinin-mediated diseases |
Country Status (14)
Country | Link |
---|---|
EP (1) | EP0846116A1 (hu) |
JP (1) | JP3071829B2 (hu) |
KR (1) | KR19990021857A (hu) |
CN (1) | CN1072220C (hu) |
AU (1) | AU706021B2 (hu) |
CA (1) | CA2222041A1 (hu) |
EA (1) | EA000669B1 (hu) |
HU (1) | HUP9900822A3 (hu) |
IL (1) | IL118369A (hu) |
NZ (1) | NZ307625A (hu) |
TR (1) | TR199600438A2 (hu) |
TW (1) | TW391960B (hu) |
WO (1) | WO1996037489A1 (hu) |
ZA (1) | ZA964101B (hu) |
Families Citing this family (47)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2189501A1 (en) * | 1995-11-06 | 1997-05-07 | Harry R. Howard | Nk-1 receptor antagonists for the treatment of cancer |
ATE219064T1 (de) * | 1995-12-18 | 2002-06-15 | Fujisawa Pharmaceutical Co | Piperazinderivative als tachykinin antagonisten |
AUPO735997A0 (en) * | 1997-06-17 | 1997-07-10 | Fujisawa Pharmaceutical Co., Ltd. | Piperazine derivatives |
DE59814233D1 (de) * | 1997-08-27 | 2008-07-03 | Solvay Pharm Gmbh | Indolmethyl-N,N'-bisacylpiperazine als Neurokininrezeptorantagonisten |
DE19824865A1 (de) * | 1997-08-27 | 1999-03-04 | Solvay Pharm Gmbh | Neue Harnstoffderivate |
US6833373B1 (en) | 1998-12-23 | 2004-12-21 | G.D. Searle & Co. | Method of using an integrin antagonist and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia |
DE10036818A1 (de) * | 2000-07-28 | 2002-02-07 | Solvay Pharm Gmbh | Neue N-Triazolylmethyl-Piperazinderivate als Neurokininrezeptor-Antagonisten |
UA75425C2 (en) * | 2001-07-09 | 2006-04-17 | Piperazine oxime derivatives with antagonistic activity to nk-1 receptor, use thereof, a pharmaceutical composition based thereon, a method for producing and a method for producing intermediary compounds | |
UA77515C2 (en) | 2002-04-04 | 2006-12-15 | Diazabicyclo alkane derivatives possessing neuroldnin-nk1 receptor antagonistic activity | |
MX2007000428A (es) | 2004-07-15 | 2008-03-05 | Amr Technology Inc | Tetrahidroisoquinolinas sustituidas con arilo y heteroarilo y uso de las mismas para bloquear la captacion de norepinefrina, dopamina y serotonina. |
ATE550019T1 (de) | 2005-05-17 | 2012-04-15 | Merck Sharp & Dohme | Cis-4-ä(4-chlorophenyl)sulfonylü-4-(2,5- difluorophenyl)cyclohexanepropansäure zur behandlug von krebs |
CA2615403C (en) | 2005-07-15 | 2015-06-16 | Amr Technology, Inc. | Aryl-and heteroaryl-substituted tetrahydrobenzazepines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin |
AU2006297443B2 (en) | 2005-09-29 | 2010-08-12 | Merck Sharp & Dohme Corp. | Acylated spiropiperidine derivatives as melanocortin-4 receptor modulators |
GB0603041D0 (en) | 2006-02-15 | 2006-03-29 | Angeletti P Ist Richerche Bio | Therapeutic compounds |
CA2664113C (en) | 2006-09-22 | 2013-05-28 | Merck & Co., Inc. | Use of platencin and platensimycin as fatty acid synthesis inhibitors to treat obesity, diabetes and cancer |
US20110218176A1 (en) | 2006-11-01 | 2011-09-08 | Barbara Brooke Jennings-Spring | Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development |
EP2109608B1 (en) | 2007-01-10 | 2011-03-23 | Istituto di Richerche di Biologia Molecolare P. Angeletti S.p.A. | Amide substituted indazoles as poly(adp-ribose)polymerase (parp) inhibitors |
CN101641099A (zh) | 2007-01-24 | 2010-02-03 | 葛兰素集团有限公司 | 包含3,5-二氨基-6-(2,3-二氯苯基)-1,2,4-三嗪或r(-)-2,4-二氨基-5-(2,3-二氯苯基)-6-氟甲基嘧啶和nk1的药物组合物 |
US8106086B2 (en) | 2007-04-02 | 2012-01-31 | Msd K.K. | Indoledione derivative |
WO2008147864A2 (en) * | 2007-05-22 | 2008-12-04 | Xenon Pharmaceuticals Inc. | Methods of using piperazine compounds in treating sodium channel-mediated diseases or conditions |
JP5501227B2 (ja) | 2007-06-27 | 2014-05-21 | メルク・シャープ・アンド・ドーム・コーポレーション | ヒストンデアセチラーゼ阻害剤としての4−カルボキシベンジルアミノ誘導体 |
AU2009222122A1 (en) | 2008-03-03 | 2009-09-11 | Tiger Pharmatech | Tyrosine kinase inhibitors |
US9156812B2 (en) | 2008-06-04 | 2015-10-13 | Bristol-Myers Squibb Company | Crystalline form of 6-[(4S)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine |
EP2413932A4 (en) | 2009-04-01 | 2012-09-19 | Merck Sharp & Dohme | INHIBITORS OF AKT ACTIVITY |
KR20120034644A (ko) | 2009-05-12 | 2012-04-12 | 알바니 몰레큘라 리써치, 인크. | 아릴, 헤테로아릴, 및 헤테로사이클 치환된 테트라하이드로이소퀴놀린 및 이의 용도 |
EP2429293B1 (en) | 2009-05-12 | 2014-10-29 | Bristol-Myers Squibb Company | CRYSTALLINE FORMS OF (S)-7-([1,2,4]TRIAZOLO[1,5-a]PYRIDIN-6-YL)-4-(3,4-DICHLOROHPHENYL)-1,2,3,4-TETRAHYDROISOQUINOLINE AND USE THEREOF |
ES2662072T3 (es) | 2009-05-12 | 2018-04-05 | Albany Molecular Research, Inc. | 7-([1,2,4]triazolo[1,5-a]piridin-6-il)-4-(3,4-diclorofenil)-1,2,3,4-tetrahidroisoquinolina y uso de la misma |
KR101485645B1 (ko) | 2009-10-14 | 2015-01-22 | 머크 샤프 앤드 돔 코포레이션 | p53 활성을 증가시키는 치환된 피페리딘 및 그의 용도 |
WO2011163330A1 (en) | 2010-06-24 | 2011-12-29 | Merck Sharp & Dohme Corp. | Novel heterocyclic compounds as erk inhibitors |
CN107090456B (zh) | 2010-08-02 | 2022-01-18 | 瑟纳治疗公司 | 使用短干扰核酸的RNA干扰介导的联蛋白(钙粘蛋白关联蛋白质),β1基因表达的抑制 |
HUE044815T2 (hu) | 2010-08-17 | 2019-11-28 | Sirna Therapeutics Inc | Hepatitisz B vírus (HBV) génexpressziójának RNS-interferencia közvetített gátlása, rövid interferáló nukleinsav (SINS) alkalmazásával |
US8883801B2 (en) | 2010-08-23 | 2014-11-11 | Merck Sharp & Dohme Corp. | Substituted pyrazolo[1,5-a]pyrimidines as mTOR inhibitors |
WO2012030685A2 (en) | 2010-09-01 | 2012-03-08 | Schering Corporation | Indazole derivatives useful as erk inhibitors |
US9242981B2 (en) | 2010-09-16 | 2016-01-26 | Merck Sharp & Dohme Corp. | Fused pyrazole derivatives as novel ERK inhibitors |
WO2012058210A1 (en) | 2010-10-29 | 2012-05-03 | Merck Sharp & Dohme Corp. | RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACIDS (siNA) |
US9351965B2 (en) | 2010-12-21 | 2016-05-31 | Merck Sharp & Dohme Corp. | Indazole derivatives useful as ERK inhibitors |
CN103732592A (zh) | 2011-04-21 | 2014-04-16 | 默沙东公司 | 胰岛素样生长因子-1受体抑制剂 |
US9023865B2 (en) | 2011-10-27 | 2015-05-05 | Merck Sharp & Dohme Corp. | Compounds that are ERK inhibitors |
EP3919620A1 (en) | 2012-05-02 | 2021-12-08 | Sirna Therapeutics, Inc. | Short interfering nucleic acid (sina) compositions |
CA2882950A1 (en) | 2012-09-28 | 2014-04-03 | Merck Sharp & Dohme Corp. | Novel compounds that are erk inhibitors |
LT2925888T (lt) | 2012-11-28 | 2018-01-10 | Merck Sharp & Dohme Corp. | Vėžio gydymo kompozicijos ir būdai |
BR112015013611A2 (pt) | 2012-12-20 | 2017-11-14 | Merck Sharp & Dohme | composto, e, composição farmacêutica |
WO2014120748A1 (en) | 2013-01-30 | 2014-08-07 | Merck Sharp & Dohme Corp. | 2,6,7,8 substituted purines as hdm2 inhibitors |
US20160194368A1 (en) | 2013-09-03 | 2016-07-07 | Moderna Therapeutics, Inc. | Circular polynucleotides |
US10947234B2 (en) | 2017-11-08 | 2021-03-16 | Merck Sharp & Dohme Corp. | PRMT5 inhibitors |
US20210309688A1 (en) | 2018-08-07 | 2021-10-07 | Merck Sharp & Dohme Corp. | Prmt5 inhibitors |
US20210277009A1 (en) | 2018-08-07 | 2021-09-09 | Merck Sharp & Dohme Corp. | Prmt5 inhibitors |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2097142T3 (es) * | 1989-02-10 | 1997-04-01 | Otsuka Pharma Co Ltd | Derivados de indol, su preparacion y medicamento que los contiene destinado para la prevencion y para el tratamiento de la nefritis. |
IL111730A (en) * | 1993-11-29 | 1998-12-06 | Fujisawa Pharmaceutical Co | Piperazine derivatives, processes for their preparation and pharmaceutical preparations containing them |
-
1996
- 1996-05-21 EA EA199700425A patent/EA000669B1/ru not_active IP Right Cessation
- 1996-05-21 JP JP8535553A patent/JP3071829B2/ja not_active Expired - Fee Related
- 1996-05-21 NZ NZ307625A patent/NZ307625A/xx unknown
- 1996-05-21 CA CA002222041A patent/CA2222041A1/en not_active Abandoned
- 1996-05-21 HU HU9900822A patent/HUP9900822A3/hu unknown
- 1996-05-21 EP EP96915200A patent/EP0846116A1/en not_active Ceased
- 1996-05-21 AU AU57031/96A patent/AU706021B2/en not_active Ceased
- 1996-05-21 CN CN96195744A patent/CN1072220C/zh not_active Expired - Fee Related
- 1996-05-21 KR KR1019970708331A patent/KR19990021857A/ko not_active Application Discontinuation
- 1996-05-21 WO PCT/JP1996/001335 patent/WO1996037489A1/en not_active Application Discontinuation
- 1996-05-22 ZA ZA964101A patent/ZA964101B/xx unknown
- 1996-05-22 IL IL11836996A patent/IL118369A/xx active IP Right Grant
- 1996-05-23 TW TW085106105A patent/TW391960B/zh not_active IP Right Cessation
- 1996-05-24 TR TR96/00438A patent/TR199600438A2/xx unknown
Also Published As
Publication number | Publication date |
---|---|
EP0846116A1 (en) | 1998-06-10 |
NZ307625A (en) | 1999-02-25 |
IL118369A (en) | 2000-06-01 |
CN1072220C (zh) | 2001-10-03 |
WO1996037489A1 (en) | 1996-11-28 |
TW391960B (en) | 2000-06-01 |
IL118369A0 (en) | 1996-09-12 |
AU5703196A (en) | 1996-12-11 |
TR199600438A2 (tr) | 1996-12-21 |
CA2222041A1 (en) | 1996-11-28 |
AU706021B2 (en) | 1999-06-03 |
JP3071829B2 (ja) | 2000-07-31 |
ZA964101B (en) | 1996-07-29 |
EA199700425A1 (ru) | 1998-12-24 |
JPH11505830A (ja) | 1999-05-25 |
KR19990021857A (ko) | 1999-03-25 |
HUP9900822A3 (en) | 1999-11-29 |
CN1191533A (zh) | 1998-08-26 |
EA000669B1 (ru) | 2000-02-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HUP9900822A2 (hu) | Piperazinszármazékok, eljárás előállításukra, ezeket tartalmazó gyógyszerkészítmények és eljárás tachikinin-mediált betegségek kezelésére | |
HUT58334A (en) | Process for producing diazines and pharmaceutical compositions containing them as active components | |
DE69723869D1 (de) | Heterozyklische verbindungen, verfahren zu ihrer herstellung, pharmazeutische zusammensetzungen die diese enthalten und ihre anwendung in der behandlung von diabetis und verwandten krankheiten | |
HUT68357A (en) | Heterocyclic-cyclic-amine derivatives, pharmaceutical compositions containing them and process for their production | |
PL294736A1 (en) | Method of obtaining novel heterocyclic derivatives | |
MX9603520A (es) | Derivados del acido hidroxamico y acido carboxilico, procesos para su preparacion y su uso. | |
DE59409311D1 (de) | Aminosäurederivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung | |
HUP9802762A2 (hu) | Difenil-metilén-piperidin-származékok, e vegyületeket tartalmazó gyógyászati készítmények, eljárás előállításukra és alkalmazásuk | |
RU94042907A (ru) | Производные имидазопиридина, способ их получения, фармацевтическая композиция и способ ее получения | |
DE69200160D1 (de) | Angiotensin-II-Antagonisten. | |
RU95111308A (ru) | Производные 2-амино-4-фенил-4-оксомасляной кислоты, способы получения, фармацевтическая композиция | |
DE59508961D1 (de) | Verwendung von weihrauch zur behandlung der alzheimer-krankheit | |
TR200101163T2 (tr) | Safra suyu ikameli fenil-alkenoilguanidinler, üretim yöntemleri, kullanımları | |
ATE225171T1 (de) | Aminosäurederivate zur behandlung von schlaganfall | |
ATE81118T1 (de) | Strontiumsalz, verfahren zu dessen herstellung und arzneimittel, die es enthalten. | |
WO1996031208A3 (de) | Verwendung von substituierten piperidin- oder pyrrolidinverbindungen zur behandlung von sigma-rezeptor modulierten krankheiten | |
DE69917668D1 (de) | Substanz gm-95, verfahren zu ihrer herstellung und ihre verwendung | |
DE69421457T2 (de) | Verwendung von N-(Pyridinyl)-1H-Indol-1-Aminen zur Herstellung eines Medikamentes zur Behandlung von zwangsneurotischen Erkrankungen | |
AP9701142A0 (en) | 4,4-(Disubstituted) cyclohexan-1-ols monomers and related compounds. | |
DE69619868T2 (de) | Piperazinylalkylthiopyrimidin derivate, diese enthaltende pharmazeutische zusammensetzungen und verfahren zu deren herstellung | |
ATE421961T1 (de) | Piperidinderivate, verfahren zu deren herstellung und pharmazeutische zusammensetzung zur behandlung von alzheimer-krankheit, die diese derivate enthält | |
EP0822260A4 (en) | SUBSTANCE FA-70D, METHOD OF MANUFACTURE AND USES | |
ATE186640T1 (de) | Verwendung von efaroxan und dessen derivaten zur herstellung eines arzneimittels zur behandlung neurogenerativer erkrankungen | |
BRPI0415529A (pt) | derivados de bengamida, processos para produção dos mesmos e uso dos mesmos para tratamento de doenças cancerosas | |
DE59406844D1 (de) | Phosphonobernsteinsäurederivate und ihre verwendung als arzneimittel |